Abstract 558: MUC1*-deruxtecan kills tumors that have acquired resistance to trastuzumab containing therapeutics
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Cynthia C. Bamdad, Benoit J. Smagghe, Scott T. Moe, Kevin R. Yi, Trevor J. Grant, Mark G. Carter, Daniel S. Miller, Michael J. Nash, Jacy P. Marquez, Natalie K. Miller, JacLeen S. Nash, Robert McDermot, Andrew K. Stewart
Institution: Minerva Biotechnologies (United States)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409690875